|44.60|| +0.62 / +1.41%|
NuVasive, Inc. is a medical device company, which is focused on the design, development, and market of surgical products to treat the spine. Its products include a minimally disruptive surgical platform called Maximum Access Surgery, in addition to biologics, cervical and motion preservation products, and Intra-Operative Monitoring services. The surgical products for the spine include devices for the thoracolumbar spine, the cervical spine, and a set of motion. The product offerings that are still under development are primarily used to gain access to the spine to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft, FormaGraft, a collagen synthetic product, Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells and AttraX, a synthetic bone graft material, all used to aid the spinal fusion process. The company was founded on July 21, 1997 and is headquartered in San Diego, CA.
|Alexis V. Lukianov||Chairman & Chief Executive Officer|
|Patrick Miles||President & Chief Operating Officer|
|Quentin Blackford||Chief Financial Officer & Executive Vice President|
|G. Bryan Cornwall||Senior VP-Clinical Operations & Research|
|Kelli Howell||Vice President-Research|